Presented for research literature review only Drmic D et al
Jaka Vukojevi, Borna Vrdoljak, Dominik Malekinui, Marko Siroglavi, Marija Milavi, Kolenc, D., Alenka Boban Blagai, Lovorka Batelja, Domagoj Drmi, Sven Seiverth, & Predrag Sikiri
Pain Ther 4(2):169-178, 2015
Pod normalnim uvjetima skladitenja, molekularna struktura ovog praha je relativno stabilna
Commonly used in IV therapy, it provides fast, effective relief without sedation, helping ease headaches, soreness, and fever for a smoother recovery
In April 2025, its board of directors authorized an additional $40-billion share repurchase program, following the $30-billion authorization announced in July 2023